Nelson N. Stone, MD, presented “3DBiopsy™: Transperineal Mapping Biopsy in 2019” during the 29th Annual International Prostate Cancer Update on January 26, 2019 in Beaver Creek, Colorado.
How to cite: Stone, Nelson N. “3DBiopsy™: Transperineal Mapping Biopsy in 2019” January 26, 2019. Accessed Jan 2020. https://grandroundsinurology.com/3dbiopsy-transperineal-mapping-biopsy-in-2019/
3DBiopsy™: Transperineal Mapping Biopsy in 2019 – Summary:
Nelson N. Stone, MD, discusses the need for adequate and accurate prostate cancer identification techniques, especially when selecting patients for active surveillance. He then reviews an emerging transperineal prostate mapping biopsy system that could be an improved tool for fusion biopsy, replace current transrectal biopsy devices, and better detect and localize lesions.
According to data on the upgrading of prostate tumors at the time of radical prostatectomy, the rate of upgrading in patients with negative confirmatory tests is 54%. Physicians must recognize this when using tests such as transrectal ultrasound biopsy, MRI, and molecular classifiers to select patients for active surveillance. Furthermore, active surveillance survival outcomes data shows that patients categorized as Gleason score 7 had a 3.1 times higher prostate cancer death rate than Gleason score 6 patients. In other words, determining treatment decisions based on inaccurate detection of Gleason scores could compromise a patient’s survival. Therefore, it is essential to have extremely accurate methods for identifying prostate cancer.
Transperineal prostate mapping biopsy (TPMB) could be the solution to this unmet need. However, there is no standardization to this technique. There is no consensus regarding the amount of cores taken, core spacing, whether or not to take in-line cores, nor whether or not to increase the number of cores in cases of larger prostate volume.
This presentation previews the 3DBiopsy(TM) TPMB system with a targeted launch date in 2020. This technology could significantly assist in creating a more standardized process. It also could reduce the number of biopsies taken from patients and possibly provide enough information to guide focal ablation.
About the International Prostate Cancer Update
The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. Stone presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.